Concerta
Sponsors
Medical University Of Lodz, Noven Therapeutics, University of Maryland, College Park, Shire, Janssen-Ortho Inc., Canada
Conditions
22q11.2 Deletion SyndromeADHDAdult ADHDAttention Deficit Disorder With HyperactivityAttention Deficit Hyperactivity DisorderAttention-Deficit/Hyperactivity DisorderAttention-deficit hyperactivity disorderExecutive Function Disorder
Phase 1
A Drug Interaction Study of SPD503 and Concerta Administered Alone and In Combination in Normal Healthy Volunteers
CompletedNCT00901576
Start: 2009-05-18End: 2009-07-06Updated: 2021-06-14
A Study to Explore Plasma Levels of CONCERTA, Ritalin-SR and Novo-Methylphenidate ER-C in Healthy Volunteers
CompletedNCT01118702
Start: 2010-05-31End: 2010-06-30Updated: 2012-12-11
Biomarkers of ADHD Treatment Response
CompletedNCT05650775
Start: 2023-02-17End: 2024-03-30Updated: 2024-12-18
Phase 2
Efficacy, Safety and Tolerability of SPD485 in Children Aged 6-12 Diagnosed With ADHD
CompletedNCT00151970
Start: 2005-06-30End: 2006-10-31Updated: 2015-07-09
LAMAinDiab - lisdexamphetamine vs methylphenidate for pediatric patients with ADHD and type 1 diabetes - a randomized crossover clinical trial.
Active, not recruitingCTIS2023-506862-30-00
Start: 2024-11-24Target: 150Updated: 2025-08-25
Phase 3
Phase 4
Efficacy of Concerta in Treating ADHD in Mothers of Children With ADHD
CompletedNCT00318981
Start: 2004-12-31End: 2006-12-31Target: 40Updated: 2023-12-27
Real-World Evidence of Duration of Effect of Adhansia XR (Extended-Release) for Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD)
TerminatedNCT04507204
Start: 2020-07-30End: 2022-01-31Updated: 2023-07-27
Unknown Phase
Concerta (Methylphenidate) -To-Generic Switch Study
CompletedNCT02730572
Start: 2015-09-30End: 2016-10-31Updated: 2017-02-13
Effects of Methylphenidate on Brain and Cognition in 22q11 Deletion Syndrome
CompletedNCT04647500
Start: 2016-08-26End: 2022-09-26Updated: 2022-10-07
Neurofeedback-Based Digital Therapeutics for the Diagnosis and Treatment of ADHD in Children.
RecruitingNCT06369714
Start: 2023-02-24End: 2025-12-31Target: 210Updated: 2025-06-10